Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 ,inter alia, to consider and approve the audited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has informed BSE that its Board of Directors will meet on Tuesday, 20 May 2025 at the registered office. The main agenda is to consider and approve the audited financial results for the quarter and full financial year ended 31 March 2025. The Board will also consider recommending a dividend, if any. This is a standard advance intimation filed under SEBI's Listing Regulations, and no actual results or numbers have been disclosed yet.
No immediate impact on shareholders from this notice itself. Investors should await the audited results on 20 May for actual revenue, profit and dividend details that could influence the stock.